Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Change is not always good

Bart L. Scott

Blood (2024) 144 (4): 355–357.

https://doi.org/10.1182/blood.2024024824

Published: 2024

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

Journal Articles

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Kristin Rathje, Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2023-185991

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

Journal Articles

Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study

Christopher T. Su, Wael Saber, Aasthaa Bansal, Li Li, Ryotaro Nakamura, Corey Cutler, Bart L. Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua Roth, Winona Wright, Lotte Steuten, Deborah Mattila, Scott D Ramsey

Blood (2023) 142 (Supplement 1): 262.

https://doi.org/10.1182/blood-2023-187218

Published: 2023

Journal Articles

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael R. Savona

Blood (2023) 142 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2023-178024

Published: 2023

Journal Articles

Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

Arpita Gandhi, Andrew Artz, Catherine J. Lee, Ankur Varma, Bart L. Scott, Hye-Sook Kwon, Minyoung Youn, Chikako Yanagiba, Jeyakavitha Arulprakasam, Anne Le, Judith Shizuru, Wendy W Pang, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 470.

https://doi.org/10.1182/blood-2023-185533

Published: 2023

Journal Articles

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Blood (2023) 141 (23): 2901–2911.

https://doi.org/10.1182/blood.2023019630

Published: 2023

Includes: Supplemental data

Journal Articles

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Blood (2022) 140 (24): 2533–2548.

https://doi.org/10.1182/blood.2022015790

Published: 2022

Includes: Supplemental data

Journal Articles

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 1518–1521.

https://doi.org/10.1182/blood-2022-156936

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Bart L. Scott, Michael R. Savona, Gail J. Roboz, Karen Seiter, Daniel A. Pollyea, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 8923–8925.

https://doi.org/10.1182/blood-2022-158068

Published: 2022

Journal Articles

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Anna B. Halpern, Eduardo P Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Sioban B. Keel, Paul C. Hendrie, Bart L. Scott, Cristina Ghiuzeli, Roland B. Walter, Elihu H. Estey

Blood (2022) 140 (Supplement 1): 8999–9001.

https://doi.org/10.1182/blood-2022-159882

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

Daniel A. Pollyea, Jaroslaw P. Maciejewski, Gail J. Roboz, Karen Seiter, Bart L. Scott, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 11844–11846.

https://doi.org/10.1182/blood-2022-156679

Published: 2022

Journal Articles

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann, Anita Badbaran, Rachel Beth Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Arnold Ganser, Christina Rautenberg, Bruno Cassinat, Felicitas R Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 828–829.

https://doi.org/10.1182/blood-2022-158900

Published: 2022

Journal Articles

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, Guillermo Garcia-Manero, David L. Grinblatt, Rami S. Komrokji, Michael R. Savona, Harry P. Erba, Gail J. Roboz, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Ali McBride, Bart L. Scott

Blood (2022) 140 (Supplement 1): 9818–9820.

https://doi.org/10.1182/blood-2022-158075

Published: 2022

Journal Articles

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Piyanuch Kongtim, Mary-Elizabeth M. Percival, Timothy J Martins, Guangrong Qin, Niall Curley, Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker

Blood (2022) 140 (Supplement 1): 1200–1202.

https://doi.org/10.1182/blood-2022-165801

Published: 2022

Journal Articles

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

Noam E. Kopmar, Megan Othus, Olivia Gilbert, Kelda Schonhoff, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Paul C. Hendrie, Bart L. Scott, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 3199–3201.

https://doi.org/10.1182/blood-2022-166526

Published: 2022

Journal Articles

The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Ronald M. Sobecks, Betul Oran, Bart L. Scott, Wael Saber, Ryotaro Nakamura

Blood (2021) 138 (Supplement 1): 417.

https://doi.org/10.1182/blood-2021-146673

Published: 2021

Journal Articles

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Nico Gagelmann, Anita Badbaran, Markus Ditschkowski, Victoria Panagiota, Bruno Cassinat, Michael Heuser, Felicitas Thol, Christine Wolschke, Rachel B. Salit, Marie Robin, Dietrich W. Beelen, Bart L. Scott, Nicolaus Kroeger

Blood (2021) 138 (Supplement 1): 314.

https://doi.org/10.1182/blood-2021-152712

Published: 2021

Journal Articles

Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation

Simone K. Feurstein, Amy M. Trottier, Noel Estrada-Merly, Matthew Pozsgai, Kelsey McNeely, Michael W. Drazer, Bart L. Scott, Betul Oran, Coleman Lindsley, Ryotaro Nakamura, Ronald M. Sobecks, Soyoung Kim, Stephen R. Spellman, Wael Saber, Lucy A. Godley

Blood (2021) 138 (Supplement 1): 320.

https://doi.org/10.1182/blood-2021-148866

Published: 2021

NARROW

Change is not always good

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only